Aktienanalyse zu Cybin Inc (HELP)HELPCybin Inc

Helus Pharma Inc., formerly Cybin Inc., is a Canada-based clinical stage pharmaceutical company. It is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. The Company's proprietary NSAs are intended to address the unmet need for people who suffer from depression, anxiety, and other mental health conditions. The Company is developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. It has developed EMBARK, which incorporates evidence-based therapies (EBTs), empirically supported treatments (ESTs), and provides session monitors with the training needed to support participants safely and effectively through treatment sessions in clinical trials. Its other pipeline product in development is HLP005. It operates in the Healthcare sector.

Cybin Inc (HELP) appears to be a good buy right now, with a current price of $11.80 and a significant upside potential reflected in analyst price targets, such as Barclays at $35 and TD Cowen at $62. The stock has shown a year-to-date change of +42.51%, indicating strong momentum. However, the main risk is the negative earnings trend, with a net income loss of CAD 46,995,000 projected for Q4 2026, which investors should consider.